Photo of Lara E. Davis, MD

Lara E. Davis MD

Dr. Davis received her undergraduate degree at Wellesley College and her M.D. from OHSU.  She returned to the East Coast for residency training before completing her oncology training at OHSU.  Dr. Davis is board-certified in both Medical Oncology and Pediatric Hematology/Oncology.

Education

  • M.D., Oregon Health & Science University, Portland Oregon 2005
  • Residency:

    • Harvard - combined internal medicine-pediatrics residency program, 2005-2009
  • Fellowship:

    • Medical oncology and pediatric hematology/oncology, Oregon Health & Science University, 2009-2013
  • Certifications:

    • American Board of Internal Medicine, 2009

Memberships and associations

  • American Society of Clinical Oncology

Publications

  • "CDK4/6 Inhibitors : The Mechanism of Action May Not Be as Simple as Once Thought." Cancer Cell  In: , Vol. 34, No. 1, 09.07.2018, p. 9-20.
  • "Epirubicin and Ifosfamide with Preoperative Radiation for High-Risk Soft Tissue Sarcomas." Annals of Surgical Oncology In: , Vol. 25, No. 4, 01.04.2018, p. 920-927.
  • "Osteosarcoma, chondrosarcoma, and chordoma." Journal of Clinical Oncology In: , Vol. 36, No. 2, 10.01.2018, p. 188-193.
  • "Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas." Cell  In: , Vol. 171, No. 4, 02.11.2017, p. 950-965.e28.
  • "Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028) : a multicentre, two-cohort, single-arm, open-label, phase 2 trial." The Lancet Oncology  In: , Vol. 18, No. 11, 01.11.2017, p. 1493-1501.
  • "Clinical trial enrollment of adolescents and young adults with sarcoma." Cancer  In: , Vol. 123, No. 18, 15.09.2017, p. 3434-3440.
  • "Integration of genomic, transcriptomic and functional profiles of aggressive osteosarcomas across multiple species." Oncotarget  In: , Vol. 8, No. 44, 2017, p. 76241-76256.
  • "An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101." Cancer Discovery In: , Vol. 5, No. 10, 01.10.2015, p. 1049-1057.
  • "Erratum : Functionally defined therapeutic targets in diffuse intrinsic pontine glioma(Nature Medicine (2015) 21 (555-559) DOI: 10.1038/nm.3855)." Nature Medicine  In: , Vol. 21, No. 7, 07.07.2015, p. 827.
  • "Preoperative Therapy for Extremity Soft Tissue Sarcomas." Current Treatment Options in Oncology In: , Vol. 16, No. 6, 16.06.2015.
  • "Functionally defined therapeutic targets in diffuse intrinsic pontine glioma." Nature Medicine  In: , Vol. 21, No. 6, 04.05.2015, p. 555-559.
  • "An integrated approach to anti-cancer drug sensitivity prediction." IEEE/ACM Transactions on Computational Biology and Bioinformatics  In: , Vol. 11, No. 6, 6808481, 01.11.2014, p. 995-1008.
  • "Inference of dynamic biological networks based on responses to drug perturbations." Tijdschrift voor Urologie  In: , Vol. 2014, No. 1, 17.01.2014, p. 1-16.
  • "A case study of personalized therapy for osteosarcoma." Pediatric Blood and Cancer  In: , Vol. 60, No. 8, 08.2013, p. 1313-1319.
  • "A new approach for prediction of tumor sensitivity to targeted drugs based on functional data." BMC Bioinformatics  In: , Vol. 14, No. 1, 239, 29.07.2013.
  • "Overcoming autopsy barriers in pediatric cancer research." Pediatric Blood and Cancer  In: , Vol. 60, No. 2, 02.2013, p. 204-209.
  • "Personalized cancer care : Opportunities and challenges in pediatric neuro-oncology." Pediatric Blood and Cancer  In: , Vol. 59, No. 1, 15.07.2012, p. 1-2.
  • "Combination therapy design for targeted therapeutics from a drug-protein interaction perspective."   Proceedings - IEEE International Workshop on Genomic Signal Processing and Statistics. 2012. p. 58-61 6507726.
  • "Analyzing pathway design from drug perturbation experiments."   2012 IEEE Statistical Signal Processing Workshop, SSP 2012. 2012. p. 552-555 6319757.

Additional information

Edit profile